Summary

● The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

● The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.


Strengths

● Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 68% by 2025.

● The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.

● Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.

● Thanks to a sound financial situation, the firm has significant leeway for investment.

● Over the last twelve months, the sales forecast has been frequently revised upwards.

● Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.

● For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.

● Analysts covering this company mostly recommend stock overweighting or purchase.

● The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

● Historically, the company has been releasing figures that are above expectations.


Weaknesses

● The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 36.17 times its estimated earnings per share for the ongoing year.

● The company's "enterprise value to sales" ratio is among the highest in the world.

● The company appears highly valued given the size of its balance sheet.

● The company is highly valued given the cash flows generated by its activity.

● The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.

● The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.